Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

avotaciclib

An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CDK1 inhibitor BEY1107
Code name:BEY 1107
BEY-1107
BEY-A
BEY1107
BEY1107G
BEY1107P
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search